Table 3.
Incidence of adverse reactions
| Adverse reaction | No. of patients | Incidence (%) |
|---|---|---|
| Constitutional | ||
| Fatigue | 3 | 6 |
| Myalgias/weakness | 3 | 6 |
| Allergic reaction | 2 | 4 |
| Cardiovascular | ||
| Arrhythmia | 2 | 4 |
| Chest pain/ischemia | 2 | 4 |
| Neurological | ||
| Dizziness | 1 | 2 |
| Syncope | 4 | 9 |
| Hallucinations | 1 | 2 |
| Seizure | 1 | 2 |
| Hematological | ||
| Neutropenia | 2 | 4 |
| Infection | 7 | 15 |
| Anemia | 2 | 4 |
| Thrombocytopenia | 1 | 2 |
| Bleeding | 3 | 6 |
| Metabolism | ||
| Electrolyte disturbances | 9 | 19 |
| Hepatic dysfunction | 3 | 6 |
| Gastrointestinal | ||
| Constipation | 1 | 2 |
| Diarrhea | 3 | 6 |
| Ileus | 1 | 2 |
| Pulmonary | ||
| Dyspnea | 5 | 11 |
Type and incidence rates of adverse reactions included in the toxicity analysis of the study using the National Cancer Institute (NCI) Common Toxicity Criteria (version 2.0). Only adverse events graded as 3 (no grade 4 adverse reactions were experienced on this trial), and those that were judged to be possibly, probably or definitely related to study medication were included.